Bivision Pharmaceuticals

Bivision Pharmaceuticals (晶核生物, also known as CoreVision Biopharma) is a China-based biotech company founded in 2021 by CEO Yu Haihua and three other experienced drug development scientists, specializing in targeted radiopharmaceuticals—specifically theranostic targeted radionuclide therapy (TRT) that combines visualization with treatment . The company has built a proprietary technology platform for targeted nuclear drug development and established a complete R&D chain, positioning itself with early-mover advantages in China's targeted radiopharma sector .

In funding, Bivision has progressed through multiple rounds with consistent backing from Gaorong Ventures, which led its nearly RMB 100 million angel round in 2022 and continued to invest in subsequent rounds . Its Series A in July 2024 was jointly led by Huajin Capital and Huajin Avenue, with Tigermed joining as a new investor , followed by a nearly RMB 400 million Series B in May 2026 co-led by Pudong Venture Capital, Zhangjiang Sci-Tech Investment, and IDG Capital, again with Gaorong Ventures increasing its stake . The company is headquartered in Shanghai with operations in Nanjing, and its capital is directed toward confirmatory clinical studies for its core pipeline, platform iteration, and building a radiopharmaceutical R&D center .